Background. Emergence of extensively drug-resistant (XDR) bacteria has forced clinicians to use off-label antimicrobial agents such as tigecycline. We present our experience on salvage use of tigecycline for the treatment of infections caused by XDR Gramnegative bacteria in critically ill children and review published cases.
Emergence of multidrug-resistance (MDR) and especially of extensive drug-resistance (XDR) in nosocomial Gram-negative bacteria (GNB) leaves limited therapeutic options. This forces clinicians to use off-label antimicrobial agents for salvage therapy especially in children, where pharmacokinetic, safety, and efficacy data are missing [1] [2] [3] [4] [5] [6] [7] [8] [9] .
Tigecycline is the first clinically available antimicrobial agent of a new class of antimicrobials called glycylcyclines. It has broad spectrum of activity including MDR/XDR Gram-positive and Gram-negative bacteria, with the exception of Pseudomonas spp [10] [11] [12] . In adults, tigecycline safety and efficacy data exist [13] . However, use in pediatric patients has been extremely limited, and data are sparse including salvage therapy of case reports and small series, whereas optimal dosage has not been defined [10] [11] [12] . The aim of this study was to present our experience on the use of tigecycline as salvage therapy of infections caused by XDR Gram-negative bacteria in critically ill children and to review previously published case reports and series.
METHODS

Hippokration Hospital Analysis
This was a retrospective chart review study conducted in the pediatric departments of a tertiary-care level hospital in Thessaloniki, Macedonia, Greece between January 2009 and May 2014. The pediatric departments consist of a total of approximately 250 beds including 1 pediatric and 2 neonatal intensive care units, 1 pediatric oncology department, 1 pediatric surgical department, and 2 general pediatric departments.
Patient Identification. All hospitalized patients aged less than 18 years were evaluated for intravenous use of tigecycline using the Hospital Pharmacy database. Patients were enrolled if they received at least 2 days (4 doses) of intravenously administered tigecycline. At this time, tigecycline was prescribed only by a pediatric infectious disease consultant, as salvage therapy for critically ill children suffering from infections caused by XDR GNB.
Data Extraction
An Excel database (Microsoft Excel 2011) of patients was created including demographics and medical data. Demographic characteristics (age, sex, weight), medical history (underlying disease), information pertaining administration of tigecycline (route, dosage, duration) or other antimicrobial agents (prior or concomitant to tigecycline therapy), type of infection for which tigecycline was administered (ie, bloodstream infection [BSI], pneumonia), invasive procedures, and laboratory tests were recorded. The latter included microbiology (results of blood/bronchial or other cultures and antimicrobial susceptibility testing), biochemistry (renal and liver function), blood count and differential, erythrocyte sedimentation rate, and C-reactive protein. Evaluation of renal function included recording of creatinine and urea values, whereas coagulation was assessed using the international normalized ratio (INR), activated partial thromboplastin time (aPTT), and fibrinogen.
Definitions
A course of intravenous tigecycline administration was defined as a period of uninterrupted tigecycline administration in the same patient. Treatment with tigecycline was considered "targeted", if started after report of antimicrobial susceptibility of the implicated organism, or "empiric", if started based on surveillance data or no response to other antimicrobials.
Multidrug resistance was defined as resistance to at least 3 antimicrobial agents (of different antimicrobial categories) with intrinsic activity against the Gram-negative pathogen, and XDR was defined as resistance to at least 1 agent in all but 2 or fewer antimicrobial categories [3] . Standard definitions for nosocomial infections were used according to the Centers for Disease Control and Prevention [14] .
Outcome and Adverse Event Assessment
All patients were assessed for signs of gastrointestinal (nausea, vomiting) or other toxicity during treatment with tigecycline. The in-hospital mortality was recorded in all patients (treated for at least 2 days) as well as in those treated with at least 5 days with tigecycline. At the end of tigecycline treatment, clinical and microbiological outcomes were assessed for patients treated for at least for 5 days.
Microbiology
Identification and antimicrobial susceptibility testing of Gramnegative bacteria were performed using the VITEK 2 automated system (bioMerieux, Marcy l'Etoile, France).
Tigecycline Administration
Tigecycline formulation by Pfizer was used. Each vial contained 50 mg of dry powder. It was administered intravenously after being dissolved in normal saline and infused over 1 hour (according to the manufacturer's instructions).
Human Subjects Oversight
This study was approved by the institutional review board of the Hospital. Because it included only retrospective collection of data, the need for informed consent was deemed unnecessary.
Literature Review
Articles on tigecycline therapy in children were retrieved from PubMed by use of the term "tigecycline" as either a keyword or medical subject heading (MeSH) with the limitation "all child: 0-18 years" before March 2015. The references cited in the above articles were screened for additional cases. Articles were included if they had data at patient level regarding the antimicrobial regimen, tigecycline dosing, and outcome.
Statistics
To compare the mortality of BSIs with that of nonbacteremic infections, Fisher's exact test (GraphPad InStat Software, Inc.) was used. P < .05 was significant.
RESULTS
Hippokration Hospital Analysis
Thirteen children (7 males) with median age 8 years (range, 2.5 months-14 years) received tigecycline for ≥2 days as treatment for healthcare-associated infections (Table 1) . These infections included 5 bacteremias, 6 lower respiratory tract infections, and 3 other infections.
Most of the isolated pathogens were XDR Gram-negative bacteria with the exception of 1 case, and they included Acinetobacter baumannii (8 patients), Klebsiella pneumoniae (3 patients), and Serratia marcescens (1 patient). In most cases, pathogens were resistant to all antimicrobial agents with the exception of tigecycline (all patients) and 1 (5 of 9 isolates) or 2 (4 of 9 isolates) other antimicrobial agents (mostly colistin) ( Table 1) . Tigecycline administration was targeted in 9 cases, and empiric administration was targeted in 4 cases (mostly based on patients' colonization) ( Table 1) .
A loading dose (1.8-6.5 mg/kg; median, 4 mg/kg) was given to all but 1 case. Maintenance dose was given at 1-3.2 mg/kg q12 h (median, 1.4 mg/kg q12 h). More specifically, the maintenance dose given every 12 hours was 1-1.4 mg/kg in 7 children and 2-3.2 mg/kg in 6 children. The median duration of tigecycline administration was 12.5 days (2-26 days). Other antimicrobials, such as colistin, aminoglycosides, carbapenems, cephalosporins, and cotrimoxazole, were coadministered to these patients.
No severe adverse events were detected in these seriously ill children. Reported adverse events were mild to moderate, and no discontinuation or dose modification was needed (Table 1 ). There was no significant adverse effect of tigecycline to coagulation parameters. Overall, 7 of 13 patients died during tigecycline treatment, most of them (6 of 7) due to overwhelming sepsis.
Among the patients who received tigecycline for at least 5 days, clinical and microbiological improvement was observed in 7 of 11 (64%) and 4 of 7 (57%) patients, respectively (Table 1) . Addition of tigecycline to the antimicrobial regimen did not improve the outcome in patients who had BSI and received tigecycline for at least 5 days (3 out of 3 had clinical failure and died). In contrast, among 8 patients without BSI who received tigecycline, only 1 patient had clinical failure and died. In addition, among 6 children, who received the dose of 2-3.2 mg/kg, 2 died (including 1 case of BSI), whereas among 5 children who received the dose of 1-1.4 mg/kg, 3 died (including 2 cases of BSI).
Literature Review
In 10 published articles, a total of 19 children were reported as having received 20 courses of tigecycline (1 child received 2 courses of tigecycline) ( Table 2 ). Eight children (57% females) with a median age of 9 years were found in case reports, and 11 children (36% females) with a median age of 2 years were found in case series (1 with 2 cases and the other with 9 cases) ( Table 2) . Bloodstream infection was found in 3 case reports and in 2 children in case series. In all reported cases, hematological malignancies (5 of 19 children) were the most common underlying diseases, followed by liver transplantation (3 of 19 children) and prematurity (3 of 19 children). In 17 cases, tigecycline was administered for infections caused by Gram-negative bacteria. In 6 courses, tigecycline was given as monotherapy. Administration of a loading dose was reported in 6 of 17 courses (1.5-3 mg/kg; median, 1.5 mg/kg). In 14 courses, tigecycline was used at the dosage of 1 mg/kg every 12 hours. The median duration of the tigecycline course was 10 days. Adverse events were found in 2 case reports and 3 in case series ( Table 2 ). All case reports had favorable outcome; however, 3 of 11 children in case series died.
Analyzing data from the 2 published case series together with our cases, mortality in BSIs was 86% (6 of 7 cases), whereas in nonbacteremic cases mortality was 24% (4 of 17 cases, P = .009). Reanalyzing these data only for children treated for at least 5 days with tigecycline, mortality was 80% in children with BSI (4 of 5 children died), whereas in children with nonbacteremic infections mortality was 24% (4 of 17 children died, P = .039).
DISCUSSION
In this report, we present a case series of children who received tigecycline as salvage therapy for serious infections due to MDR/XDR bacteria and review all previously published cases reported in PubMed. This combined review of ours and previously published cases presents the largest experience of tigecycline administration in children in the English literature. NA, not applicable; P, persistence; S, survived; STP, septic thrombophlebitis; SXT, co-trimoxazole; TEC, teicoplanin; VRC, voriconazole. *Colonization. **For 6 days 50 mg×2 and then 25 mg×2. ***Adverse events could not be assessed because this patient suffered from multiple organ failure and tigecycline was coadministered with other 4 anti-microbialagents. This patient had elevated LFTs for a long time before tigecycline was started.
a The patient suffered from neutropenic enterocolitis.
b These patients had elevated ALT and AST before administration of tigecycline due to underlying disease and concomitant treatment. Tigecycline has been approved since 2005 for use in adults (patients 18 years age and older) with complicated intra-abdominal infections, complicated skin and soft tissue infections, as well as community-acquired pneumonia at a loading dose of 100 mg followed by 50 mg twice daily [13] . There were 2 alerts from US Food and Drug Administration (FDA) in 2010 and 2013 for an increased risk of death associated with tigecycline use for the treatment of a variety of serious infections in adults [13] . According to these FDA warnings, which were based on a meta-analysis of randomized clinical trials, tigecycline should be reserved for cases with very few or no other alternative antimicrobial agents [15] . However, European Medicine Agency (EMA) Committee for Medicinal Products for Human Use concluded that tigecycline benefits continue to outweigh its risks [16] . Nonetheless, in real world of clinical care, off-label use of tigecycline especially for infections caused by MDR/XDR bacteria is widespread in adult critically ill patients [13, 17, 18] . For children, the FDA postulated that tigecycline is not recommended unless alternative treatment is not suitable [15] , which is in line with EMA with the same warning applicable in children older than 8 years (not recommended for <8 years) [16] .
Dosage of tigecycline in children is based on 1 pharmacokinetics (PK) study that has been conducted in children aged 8 to 11 years old [19] . In this open-label, ascending-dose study, administration of 1-1.2 mg/kg tigecycline every 12 hours provided similar drug exposure (area under the curve) with adult studies, in which tigecycline was used at a standard dose of 100 mg as a loading dose followed by 50 mg twice a day. However, no PK data exist for infants and children younger than 8 years. In most pediatric cases, tigecycline was used at a dose of 1-1.2 mg/kg every 12 hours [11, 12, [20] [21] [22] [23] , whereas Jaspan et al [24] used a dose of 2 mg/kg every 12 hours. In our case series, half of the patients received 1-1.4 mg/kg every 12 hours and the other half received a higher dose (2-3.2 mg/kg every 12 hours). Although in the single PK study in older children no loading dose was studied, we used loading dose in all but 1 case according to the relative data on adults [19] .
In our case series, there was no discontinuation or dose reduction of tigecycline due to adverse events. Although tigecycline was used in combination with other antimicrobial agents, it was well tolerated in all patients. Nausea and vomiting were the most frequent adverse events in studies conducted in adults as well as in the only open-label study in children aged 8-11 years old [13, 19] . Most of our patients were critically ill and mechanically ventilated patients, and therefore it was difficult to assess nausea and vomiting. However, among published pediatric cases, adverse events possibly associated to tigecycline use have been documented, namely acute pancreatitis [25] , hypertension [22] , neutrophil engraftment delay [26] , and diarrhea [12] . In critically ill adult patients who received higher than recommended doses of tigecycline (150 or 200 mg as loading dose followed by 75 or 100 mg, respectively), adverse events were mild to moderate according to a recent randomized clinical trial [27] . However, Routsi et al [28] found a decrease in fibrinogen concentration and an increase in INR and aPTT values in critically ill adult patients treated with high tigecycline doses; such an adverse event was not reported in children and was not found in our series.
In most pediatric cases, tigecycline was added to antimicrobial regimen. This is in line with the most recent published reports on tigecycline use in adults for infections caused by multidrug-resistant bacteria [13, 29] . Moreover, in 2015, a report of a cohort of 661 adults with infections caused by K pneumoniae carbapenemase (KPC)-producing K pneumoniae isolates found that survival was improved only when treatment included at least 2 in vitro active, antimicrobial agents [30] . Combining data from our report and literature review, 11 of 33 cases were caused by KPC-producing K pneumoniae isolates.
When we combined data from published cases and case series with our cases we found that the overall mortality was significantly higher in children with BSIs receiving tigecycline than in children with nonbacteremic infections. By comparison, one study of adult patients receiving off-label tigecycline for BSIs found clinical success in 80% of them [6] . This might be explained by the fact that tigecycline is off-label and without dose recommendations in pediatrics, so clinicians would prescribe it in serious infections as salvage therapy and later than in adults in the same critical condition.
In our case series, we used 2 different dosing regimens for tigecycline (1-1.2 mg/kg per dose and 2-3.2 mg/kg per dose) because of the lack of PK data especially in infants and young children. Efficacy of high dosage for ventilator-associated pneumonia (VAP) in critically ill adult patients was assessed in a phase II randomized controlled trial [27] . According to this study, a higher tigecycline dose (150 or 200 mg daily) may have better efficacy for VAP. In addition, a retrospective study in intensive care unit patients found that a high dose (200 mg daily) of tigecycline improved outcome mainly in patients with VAP [18] . However, a systematic review on high doses of tigecycline found that all of these data are limited and more data are needed to support high-dose regimens [17] .
The obvious limitation of this observational case-series study is the lack of a control group. In addition, tigecycline was used in combination with other antimicrobial agents and without measurement of drug levels. For these reasons, definite conclusions on safety and efficacy of tigecycline use in critically ill pediatric patients cannot be drawn. However, this case series contributes to our knowledge for salvage therapy with tigecycline to critically ill children.
CONCLUSIONS
Tigecycline administered concomitantly with other agents, as salvage therapy in critically ill children with severe infections predominantly caused by MDR/XDR Gram-negative bacteria, was well tolerated and demonstrated relatively good clinical response in nonbacteremic patients. However, until more definitive comparative and PK-based optimal dosing data are available, tigecycline should be only used in children as salvage therapy with no alternative therapeutic options.
Notes
